Trial
NCT01392495
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
Phase IIITERMINATEDREGULATORYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Pulmonary Arterial Hypertension
Intervention
Imatinib
Why stopped
Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-08-10